Akademisyen
YUSUF KARAKAŞ
PROFESÖR
İSTANBUL KENT ÜNİVERSİTESİ SAĞLIK HİZMETLERİ MESLEK YÜKSEKOKULU TIBBİ HİZMETLER VE TEKNİKLER BÖLÜMÜ
- Ana Dal Sağlık Bilimleri Temel Alanı
- Yan Dal Tıbbi Onkoloji (İç Hastalıkları)
Kayıtlı çıktılara kısa bakış — ayrıntılar aşağıda.
- Makale 53
- Proje 0
- Kitap 6
- Bildiri 50
- Patent 0
- Sanatsal 0
Scopus (SJR)
Q1
11
Q2
17
Q3
15
Q4
5
WoS (JCR)
Q1
5
Q2
13
Q3
10
Q4
19
TR Index
7
makale
Alan+yıl+tür normalize OpenAlex yüzdelik — Clarivate ESI / SciVal değildir.
Üst %1 makale
0
Üst %10 makale
5
Ort. yüzdelik
54.0%
Üst %1 payı
0.0%
Üst %10 payı
11.1%
Makaleler
YÖKSİS ve OpenAlex kaynak ayrımıyla makaleler; quartile ve TR Index ile daraltabilirsiniz.
Makale listesi
- 2025 Ostracism in Adolescent Cancer Patients and Predictors (OSTRACA Study): A Pilot Study of the Palliative Care Working Committee of the Turkish Oncology Group (TOG) YÖKSİS TR Index OpenAlex 8.1%
- 2025 Real-world treatment efficacy of ribociclib or palbociclib plus fulvestrant in hormone receptor-positive/HER2-negative metastatic breast cancer: Turkish Oncology Group (TOG) Study YÖKSİS SJR Q2 JCR Q3 OpenAlex 88.9%
- 2025 HER2-low expression in patients with hormone receptor positive and HER2 negative advanced breast cancer treated with ribociclib or palbociclib in combination with endocrine therapy YÖKSİS TR Index OpenAlex 69.4%
- 2024 Overall approach to building LCA and recent studies in Türkiye YÖKSİS SJR Q2 JCR Q2 OpenAlex 3.6%
- 2024 Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases YÖKSİS TR Index OpenAlex üst %10 OpenAlex 95.1%
- 2024 Activity of CDK4/6 inhibitors and parameters affecting survival in elderly patients in age-subgroups: Turkish Oncology Group (TOG) retrospective study YÖKSİS SJR Q2 JCR Q2 OpenAlex 85.4%
- 2023 PROPSEA, safety evaluation of palbociclib and ribociclib in older patients with breast cancer: A prospective real-world TOG study YÖKSİS SJR Q2 JCR Q2 OpenAlex 88.5%
- 2023 Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer YÖKSİS SJR Q1 JCR Q2 OpenAlex üst %10 OpenAlex 95.3%
- 2022 The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study YÖKSİS SJR Q1 JCR Q2 OpenAlex 60.4%
- 2022 Investigation of the validity and reliability of the Turkish version of the Functional Assessment of Cancer Therapy-Cognitive Function in cancer patients YÖKSİS SJR Q1 JCR Q3 OpenAlex 77.6%
- 2022 Real life experience of patients with locally advanced gastric and gastroesophageal junction adenocarcinoma treated with neoadjuvant chemotherapy: a Turkish oncology group study YÖKSİS SJR Q3 JCR Q4 OpenAlex 7.9%
- 2020 pPrognostic Significance of Serum Insulin-Like Growth Factor-1 in Hepatocellular Cancer Patients: A Validation Study/p YÖKSİS SJR Q2 JCR Q2 OpenAlex 62.9%
- 2020 Multimodality Treatment in Malignant Peripheral Nerve Sheath Tumors YÖKSİS TR Index SJR Q4 OpenAlex 42.4%
- 2020 Worse patient–physician relationship is associated with more fear of cancer recurrence (Deimos Study): A study of the Palliative Care Working Committee of the Turkish Oncology Group (TOG) YÖKSİS SJR Q3 JCR Q1 OpenAlex 53.4%
- 2020 Prognostic value of the 2017 World Health Organization Classification System for gastric neuroendocrine tumors: A single-center experience YÖKSİS SJR Q3 JCR Q4 OpenAlex 45.9%
- 2019 Hakkari İlinde Görülen Kanser Türlerinin ve Prevalanslarının Değerlendirilmesi YÖKSİS TR Index OpenAlex 29.1%
- 2019 Is microsatellite instability a negative prognostic factor in early stage endometrial cancer patients? YÖKSİS SJR Q1 JCR Q1
- 2019 Analysis of Fusobacterium nucleatum and Streptococcus gallolyticus in saliva of colorectal cancer patients YÖKSİS SJR Q2 JCR Q3 OpenAlex üst %10 OpenAlex 91.1%
- 2019 The role of ABO blood groups in glial neoplasms YÖKSİS SJR Q2 JCR Q4 OpenAlex 59.9%
- 2018 The Effect of Total Size of Lesions in Multifocal/Multicentric Breast Cancer on Survival YÖKSİS SJR Q2 JCR Q3 OpenAlex 41.8%